Effect of 3M-003, an imidazoquinoline, on phagocyte candidacidal activity directly and via induction of peripheral blood mononuclear cell cytokines

FEMS Immunology and Medical Microbiology

Volumn 59, Issue 1, 2010, Pages 81-89

  Brummer, Elmer ^a,b   Antonysamy, Mary A ^c   Bythadka, Lakshmi ^a   Gullikson, Gary W ^c   Stevens, David A ^a,b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c 3M COMPANY   (United States)

Author keywords

Antifungal activity; Cytokines; Imidazoquinoline; Immunomodulator; Phagocytes

Indexed keywords

3M 003; ANTIFUNGAL AGENT; GAMMA INTERFERON; INTERLEUKIN 12P40; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; IMIDAZOLE DERIVATIVE; IMMUNOLOGIC FACTOR; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CELL FUNCTION; CELL KILLING; CELL LINEAGE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; EFFECTOR CELL; FUNGAL CELL CULTURE; FUNGUS ISOLATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; IN VITRO STUDY; MACROPHAGE ACTIVATION; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SUPERNATANT; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CANDIDA; IMMUNOLOGY; MACROPHAGE; MICROBIAL VIABILITY; MONONUCLEAR CELL; PHAGOCYTE; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; BLOOD; CANDIDA; CYTOKINES; IMIDAZOLES; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; MONOCYTES; NEUTROPHILS; PHAGOCYTES; QUINOLINES;

EID: 77951960324     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2010.00664.x     Document Type: Article

References (42)

1. Akira S Takeda K (2004) Toll-like receptor signaling. Nat Rev Immunol 4 : 499 511. (Pubitemid 37221695)
2. Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A Pollack H (2007) Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 44 : 1549 1554. (Pubitemid 46871500)
3. Bellochio S, Montagnoli C, Bozza S, Gaziano R, Rossi G, Mambula SS, Vecchi A, Montorani A, Levitz SM Romani L (2004) The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 172 : 3059 3069. (Pubitemid 38263695)
4. Bottrel RLA, Yang YL, Levy DE, Tomai M Reis LFL (1999) The immune response modifier imiquimod requires STAT-1 for induction of interferons, interferon stimulated genes, and interleukin-6. Antimicrob Agents Ch 43 : 856 861. (Pubitemid 29165749)
5. Brummer E Stevens DA (1995) Antifungal mechanisms of activated murine bronchoalveolar and peritoneal macrophages for Histoplasma capsulatum. Clin Exp Immunol 102 : 65 70.
6. Buates S Matlashewski G (1999) Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 179 : 1485 1494. (Pubitemid 29246599)
7. Buates S Matlashewski G (2001) Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob Agents Ch 45 : 1137 1142. (Pubitemid 32230994)
8. Caron G, Duluc D, Fremaux I, Jeannin P, David C, Gascan H Delneste Y (2005) Direct stimulation of human T cells via TLR-5 and TLR-7/8: flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells. J Immunol 175 : 1551 1557. (Pubitemid 41023056)
9. Chapman R Faix R (2003) Invasive neonatal candidiasis: an overview. Semin Perinatol 27 : 352 356. (Pubitemid 37363187)
10. Charmoy M, Megnekou R, Allenbach C, Zweifel C, Perez C, Monnat K, Breton M, Ronet C, Launois P Tacchini-Cottier F (2007) Leishmania major induces distinct neutrophil phenotypes in mice that are resistant or susceptible to infection. J Leukocyte Biol 82 : 288 299. (Pubitemid 47230640)
11. Chosidow O Dummer R (2003) Imiquimod: mode of action and therapeutic potential. Acta Derm-Venereol 214 (suppl) : 8 11.
12. Clemons KV, Gonzalez GM, Singh G, Imai J, Espiritu M, Parmar R Stevens DA (2006) Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob Agents Ch 50 : 2650 2657. (Pubitemid 44198683)
13. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM Miller JF (2005) The TLR-7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 175 : 1983 1990. (Pubitemid 41023106)
14. Dahl MV (2002) Imiquimod: a cytokine inducer. J Am Acad Dermatol 47 : 5205 5208.
15. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS Miller JS (2007) First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 13 : 7119 7125. (Pubitemid 350276897)
16. Erbagui Z, Tuncel AA, Ergilic S Zer Y (2005) Successful treatment of antifungal and cryotherapy-resistant subcutaneous hyalohyphomycosis in an immunocompetent case with topical 5% imiquimod cream. Mycopathologia 159 : 521 526. (Pubitemid 40876669)
17. Garland S (2003) Imiquimod. Curr Opin Infect Dis 16 : 85 89. (Pubitemid 36521020)
18. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomei MA, Alkan SS Vasilakos JP (2005) Synthetic TLR agonists reveal functional differences between human TLR 7 and TLR 8. J Immunol 174 : 1259 1268.
19. Gorden KKB, Qiu XX, Binsfeld CCC, Vasilakos JP Alkan SS (2006) Cutting edge: activation of murine TLR 8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 177 : 6584 6587.
20. Gupta AK, Cherman AM Tyning SK (2004) Viral and non-viral uses of imiquimod: a review. J Cutan Med Surg 8 : 338 352.
21. Harandi AM, Sanchez J, Eriksson K Holmgren J (2003) Recent developments in mucosal immunomodulatory adjuvants. Curr Opin Investig D 4 : 156 161. (Pubitemid 36383010)
22. Harrison LI, Astry C, Kumar S Yunis C (2007) Pharmacokinetics of 852A, an imidazoquinoline toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 47 : 962 969. (Pubitemid 47094102)
23. Hart OM, Athie-Morales V, O'Connor GM Gardiner CM (2005) TLR-7/8 mediated activation of human NK cells results in accessory cell-dependent IFN-γ production. J Immunol 175 : 1636 1642. (Pubitemid 41023066)
24. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Kiyoshi Takeda K Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol 3 : 196 200. (Pubitemid 34141451)
25. Hurwitz DJ, Pincus L Kupper TS (2003) Imiquimod. A topically applied link between innate and acquired immunity. Arch Dermatol 139 : 1347 1350. (Pubitemid 37248285)
26. Megyeri K, Au WC, Rosztoczy I, Raj NB, Miller RL, Tomai MA Pitha PM (1995) Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol Cell Biol 15 : 2207 2218.
27. Netea MG Van der Meer JWM (2006) Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clin Microbiol Infec 12 : 404 409.
28. Netea MG, Van der Graff CAA, Vonk MF, Verschueren I, Van der Meer JWM Kullberg B-J (2002) The role of toll-like receptors (TLR) 2 and TLR-4 in host defense against disseminated candidiasis. Infect Immun 185 : 1483 1489. (Pubitemid 34507972)
29. Netea MG, Van der Meer JWM, Sutmuller RP, Adena GJ Kullberg B-J (2005) From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Ch 49 : 3991 3996.
30. Philbin VJ Levy O (2007) Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem Soc T 35 : 1485 1491.
31. Rementeria A, Garcia-Tobalina R Sevilla MJ (1995) Nitric oxide-dependent killing of Candida albicans by murine peritoneal cells during experimental infection. FEMS Immunol Med Mic 11 : 157 162.
32. Roeder A, Kirschning CJ, Rupec RA, Schaller M, Weindl G Korting HC (2004) Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol 42 : 485 498. (Pubitemid 40109561)
33. Sauder DN (2003) Imiquimod: modes of action. Brit J Dermatol 149 (suppl 66) : 5 8.
34. Skinner RB (2003) Imiquimod. Dermatol Clin 21 : 291 300. (Pubitemid 36529763)
35. Smith E, Schwartz M, Kawamoto H, You X, Hwang D, Liu H Scherr D (2007) Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urology 177 : 2347 2351. (Pubitemid 46726385)
36. Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Dermatol 27 : 571 577. (Pubitemid 35463873)
37. Tomai MA, Bibson SJ, Imbertson LM et al 1995) Immunomodulatory and anti-viral activities of the imidazoquinoline S-28463. Antivir Res 28 : 253 264.
38. Tsuda Y, Takahashi H, Kobayashi M, Hanafusa T, Herndon DN Suzuki F (2004) Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 21 : 215 226. (Pubitemid 39094051)
39. Uematsu S, Sato S, Yamamoto M et al 2005) Interleukin-1 receptor associated kininase-1 plays an essential role for toll-like receptor (TLR)-7 and TLR-9 mediated interferon-α induction. J Exp Med 201 : 915 923. (Pubitemid 40524461)
40. Vazquez-Torres A, Jones-Carson J Balish E (1996) Peroxynitrite contributes to candidacidal activity of nitric oxide producing macrophages. Infect Immun 64 : 3127 3133. (Pubitemid 26256155)
41. Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, Reiter MJ, Vasilakos JP Tomai MA (1999) Modulation of TH1 and TH2 cytokine production with immune response modifier R-848 and imiquimod. Cell Immunol 19 : 10 19.
42. Zhang WW Matlashewski G (2008) Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 76 : 3777 3783.